The inhibition of HNF4α did not reduce hepatic fat accumulation effectively, but it decreased the intrahepatic inflammation and NAFLD activity score compared to the control (Figure 4A). The gene discussed is HNF4A; the disease is metabolic dysfunction-associated steatotic liver disease.